DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 76 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

Neutral impactStocks

BSE shares give up gains from hopes of a CAS review

CNBC-TV18 1 hr ago·15 Sept 2026, 10:07 am

BSE shares have given up their recent gains as market sentiment cooled regarding a potential review of the Collective Investment Scheme (CAS). The stock had rallied on hopes that the regulator would intervene to protect investors, but these expectations have now faded.

For investors, this shift highlights the sensitivity of the market to regulatory news. While the initial rally was driven by optimism, the pullback suggests that investors are recalibrating their expectations for the outcome of the review.

Moving forward, the key focus will be on the official stance of the market regulator. Any further clarity or delay in the review process could trigger fresh volatility in the stock.